Study evaluates adapted activity index for canine pancreatitis
Bottom line
A prospective observational study in Animals evaluated an adapted Modified Canine Activity Index, or aMCAI, as a bedside clinical scoring tool for dogs with acute pancreatitis. In 42 dogs, investigators tracked scores on days 1, 3, and 5 and analyzed how those scores changed over time between survivors and non-survivors, aiming to test whether a streamlined clinical index could help assess severity and prognosis in a disease that remains difficult to stage consistently. The work builds on earlier pancreatitis scoring systems, including the Modified Canine Activity Index, which was adapted from the canine inflammatory bowel disease activity index, and other composite tools such as CAPS and CAPCSI. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary teams, the appeal is practical: pancreatitis cases often need repeated reassessment, but available tools vary in complexity, and biomarkers such as cPLI and CRP don't always map neatly onto day-to-day clinical status. Prior research has shown MCAI-style scoring is already being used in pancreatitis studies and clinical monitoring, while larger retrospective work suggests prognostic scores can help with risk stratification but should be interpreted cautiously, especially when predicting death in a condition with variable presentation and outcomes. A validated aMCAI could give clinicians a simpler way to serially document response to treatment, support case communication, and standardize endpoints in future trials. (academic.oup.com)
What to watch: Watch for the full paper’s cutoff values, discrimination statistics, and whether outside groups validate aMCAI against survival, hospitalization length, and biomarker trends in broader case populations. (academic.oup.com)
A new prospective study in Animals examines whether an adapted Modified Canine Activity Index, or aMCAI, can improve clinical assessment in dogs with acute pancreatitis, a condition that still lacks a universally accepted, easy-to-use severity tool. According to the study summary, the investigators followed 42 dogs with acute pancreatitis and measured aMCAI scores on days 1, 3, and 5, using a linear mixed model to compare score trajectories over time and between survivors and non-survivors. That puts the focus squarely on a question many clinicians face in practice: not just whether a dog has pancreatitis, but how sick that patient is, and whether it's improving. (pmc.ncbi.nlm.nih.gov)
That question has been hard to answer consistently in canine medicine. Acute pancreatitis in dogs has a broad and sometimes misleading presentation, with vomiting and abdominal pain common but far from universal, and diagnosis usually depends on combining history, clinical signs, imaging, and pancreatic lipase testing rather than a single gold standard test. Earlier scoring systems have tried to fill the prognostic gap, including the Organ Score, CAPCSI, CAPS, and the Modified Canine Activity Index, which was adapted from the canine inflammatory bowel disease activity index for use in pancreatitis. (mdpi.com)
The existing MCAI has already moved beyond theory and into research use. In a randomized controlled trial of fuzapladib in dogs with presumptive acute-onset pancreatitis, MCAI served as the primary clinical endpoint; the score included activity, appetite, vomiting, cranial abdominal pain, dehydration, fecal consistency, and blood in feces, with a maximum score of 19. That trial found a greater mean improvement in MCAI scores in treated dogs than in placebo controls, underscoring why clinical activity indices matter in both therapeutic studies and serial inpatient monitoring. (academic.oup.com)
At the same time, prior evidence suggests no single score should be treated as definitive. A 2024 multi-institutional retrospective analysis of 504 dogs with acute pancreatitis found that prognostic scoring systems, including MCAI, can support risk assessment, but positive test characteristics for death prediction were limited and high cutoffs should be interpreted carefully. Other work has also shown that serum CRP may correlate with MCAI over time, while pancreatic lipase and inflammatory markers do not necessarily give clinicians a clean read on clinical progression by themselves. (academic.oup.com)
That context is what makes the aMCAI study useful. If the adapted score preserves clinical relevance while improving consistency, it could become a more usable tool for general practice, emergency, and referral settings. A score that can be repeated on days 1, 3, and 5 without relying on advanced calculations or extensive lab panels may help teams standardize rounds, document response to supportive care, and communicate prognosis more clearly to pet parents. This is especially relevant in pancreatitis, where hospitalization length, intensity of monitoring, and the risk of deterioration can change quickly. (pmc.ncbi.nlm.nih.gov)
No independent expert reaction specific to this new paper was readily available in the sources I found, but the broader literature points in the same direction: clinicians need tools that capture the patient in front of them, not just a lab value. Recent reviews and research on canine pancreatitis continue to emphasize the limits of subjectivity, the imperfect correlation between biomarkers and clinical status, and the need for serial assessment rather than one-time classification. That makes an observational validation study of a practical score more than an academic exercise, particularly if it helps align bedside findings with outcomes. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the likely value of aMCAI is operational as much as scientific. A practical, repeatable score could help triage cases, identify dogs that aren't improving as expected, support treatment decisions during hospitalization, and create more consistent endpoints for future pancreatitis trials. It could also reduce some of the ambiguity that comes when cPLI, CRP, ultrasound findings, and clinical appearance don't all move in the same direction. Still, as prior large-scale data suggest, any score will need external validation and should probably be used alongside, not instead of, clinician judgment, imaging, and laboratory data. (academic.oup.com)
What to watch: The next step is whether the full publication reports strong receiver operating characteristic performance, clinically useful cutoff points, and reproducibility outside the original center, and whether future studies compare aMCAI head-to-head with CAPS, CAPCSI, APPLE, hospitalization duration, and survival in larger cohorts. (academic.oup.com)